Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 09/18/2022

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.

Summary: Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.

How satisfactory is on-demand icatibant from the patients' perspective in real life?

Summary: How satisfactory is on-demand icatibant from the patients' perspective in real life?

Inhibition of Prekallikrein for Hereditary Angioedema.

Summary: Inhibition of Prekallikrein for Hereditary Angioedema.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

Summary: Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.

A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.

Summary: A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.

Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.

Summary: Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.

How do patients and physicians communicate about hereditary angioedema in the United States?

Summary: How do patients and physicians communicate about hereditary angioedema in the United States?

Diagnosis of hereditary angioedema after thirty years of clinical manifestations.

Summary: Diagnosis of hereditary angioedema after thirty years of clinical manifestations.

HAE patient self-sampling for biomarker establishment.

Summary: HAE patient self-sampling for biomarker establishment.

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).

Summary: Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).

Argentine Consensus of the Diagnosis and Treatment of Hereditary Angioedema.

Summary: Argentine Consensus of the Diagnosis and Treatment of Hereditary Angioedema.

Management of hereditary angioedema type I and homozygous MTHFR mutation during pregnancy.

Summary: Management of hereditary angioedema type I and homozygous MTHFR mutation during pregnancy.
Showing 1-12 of 58

Last Updated: 09/18/2022